Imagion Biosystems Ltd has released a press release.
Phase 1 Study Closure and Preliminary Performance
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Notice of Extraordinary General Meeting/Proxy Form
- Imagion presents ovarian cancer data at AACR conference
- 2022 R&D Tax Refund
- Appendix 4D
- Half-Year Results Release
Later from Imagion Biosystems
- Imagion Announces Positive Results from Phase 1 Study
- Imagion Announces CEO Departure
- Appendix 4E and Preliminary Final Report
- Suspension from Quotation
- Prospectus - Convertible Notes
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems